Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2016 San Antonio Breast Cancer Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Brufsky on Cobimetinib Plus Paclitaxel in TNBC
21st Century Cures Act Passes, Priority Review in Bladder Cancer, and 2016 Highlights from SABCS and WCLC
Dr. Prat on HER2-Enriched Subtype as Strong Predictor of HER2-Targeted Treatment
Oncology Conference Articles
Dual HER2-Blockade Plus AI Shows Promise in HER2+/ER+ Breast Cancer
Data from the phase II PERTAIN trial presented late last year at the 2016 San Antonio Breast Cancer Symposium showed that adding an aromatase inhibitor (AI) to pertuzumab and trastuzumab extended progression-free survival by over 3 months versus trastuzumab plus an AI in patients with HER2-positive, HR-positive locally advanced or metastatic breast cancer.
Pegram Sheds Light on Margetuximab in HER2+ Breast Cancer
The Fc-modified monoclonal antibody margetuximab in combination with chemotherapy may offer a new treatment option for patients with HER2-positive metastatic breast cancer.
Prophylactic Treatment Reduces Neratinib-Related Toxicity in HER2+ Breast Cancer
A prophylactic treatment of loperamide plus budesonide reduced the rate of grade 3 diarrhea associated with neratinib.
Post-Mastectomy Radiation Associated With Increased Complications for Some Patients
Patients with breast cancer who received radiation therapy after undergoing a mastectomy reported increased complications and lower satisfaction.
Hurvitz Sheds Light on Abemaciclib Activity in HR+/HER2- Breast Cancer
The neoadjuvant combination of CDK4/6 inhibitor abemaciclib plus anastrazole may represent a novel therapeutic option for patients with hormone receptor-positive, HER2-negative early breast cancer.
Axillary Lymph Node Dissection Can Be Avoided for Some Patients With Breast Cancer, Study Shows
Results of a clinical trial show that an axillary lymph node dissection can be avoided for patients with large, operable tumors in the breast, no clinical signs of cancer in the axillary nodes before being treated with neoadjuvant chemotherapy, and no signs of cancer following a sentinel lymph node biopsy during surgery.
Continuous Low-Dose Ribociclib Both Safe and Active in Advanced Breast Cancer
A continuous low-dose of ribociclib demonstrated both preliminary activity and an acceptable safety profile when compared with an intermittent dose of ribociclib when combined with fulvestrant in the treatment of postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Carboplatin Response Rate Not Superior to Docetaxel in BRCA1 Methylated or Silenced TNBC
Testing for BRCA1 methylation or mRNA silencing did not predict a better response to carboplatin over docetaxel in patients with advanced triple-negative or BRCA1/2 breast cancer.
Pembrolizumab Shows Durable Responses in Heavily Pretreated TNBC
Treatment with pembrolizumab continued to show a consistent durable benefit with an additional year of follow-up for heavily pretreated patients with recurrent PD-L1-positive metastatic triple-negative breast cancer.
Pembrolizumab/Eribulin Combo Shows Promise for TNBC
The combination of pembrolizumab and eribulin demonstrated a 33.3% objective response rate for patients with metastatic triple-negative breast cancer who received 0 to 2 prior lines of therapy.
IBM's Watson Achieves High Concordance in Tumor Board Test
The artificial intelligence computer program Watson for Oncology (WFO) achieved a high degree of concordance with tumor board recommendations in a double-blinded validation study in Bengaluru, India, according to results presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
AI Therapy May Pose Cardiovascular Risk for Breast Cancer Survivors
Aromatase inhibitor (AI) therapy may pose a risk of cardiovascular disease to postmenopausal women with early-stage breast cancer, raising the possibility of a long-term complication in an era of growing survivorship when patients are treated with estrogen-targeting drugs for years.
Women With Menopausal Symptoms Less Likely to Adhere to Breast Cancer Prevention Treatment
Women who are experiencing symptoms of menopause are less likely to adhere to treatment, according to findings presented at the 2016 San Antonio Breast Cancer Symposium.
Ribociclib Shows Consistent Benefit in Advanced Breast Cancer Subgroups
A subgroup analysis of the randomized MONALEESA-2 trial showed that patients with advanced HR-positive, HER2-negative breast cancer, and visceral metastases obtained a significant benefit from treatment with the CDK4/6 inhibitor ribociclib combined with letrozole.
Sacituzumab Govitecan Elicits Durable Responses for Pretreated TNBC
Treatment with sacituzumab govitecan was well-tolerated and induced durable responses, some lasting longer than 1 year, for heavily pretreated patients with metastatic triple-negative breast cancer.
More Evidence That Scalp Cooling Devices Work, Especially During Taxane-Based Chemotherapy
Findings from the first prospective, randomized clinical trial to evaluate modern scalp-cooling demonstrate that the system is safe and effective in reducing hair loss in women being treated with chemotherapy for their breast cancer, especially for those on taxane-based regimens.
Prophylactic Regimen Reduces Neratinib-Related Diarrhea in HER2+ Breast Cancer
Prophylactic treatment with the combination of loperamide and budesonide reduced the rate of grade ≥3 diarrhea associated with neratinib to 15% compared with 39.9% observed in the ExteNET trial.
New Mechanism of Action Results Renew Interest in Eribulin
There has been renewed interest in eribulin mesylate following its FDA approval for advanced or unresectable liposarcoma and with the introduction of a growing body of preclinical work suggesting the agent has a novel anti–mesenchymal mechanism of action.
Neoadjuvant Estrogen Attack Falters in High-Risk Breast Cancer Patients
An attempt to strengthen neoadjuvant treatment of patients with locally advanced HR-positive and HER2-positive breast cancer by adding estrogen deprivation therapy to a standard regimen failed to significantly improve response rates but did illustrate the extensive toxicity of the chemotherapy agents used in this setting.
Biomarker Analysis Shows Promise for Predicting Breast Cancer Response
A biomarker analysis of participants in a phase II breast cancer trial demonstrated potential for identifying tumor markers to predict susceptibility to specific therapies.
HER2-Enriched Breast Tumor Subtype Predicts Response to HER2 Dual Blockade
-enriched subtype of HER2-positive breast cancer is a strong predictor of sensitivity to dual HER2 blockade without the use of chemotherapy.
No Clinical Benefit With Adjuvant Ibandronate in Postmenopausal Breast Cancer
Adjuvant ibandronate (Boniva) added to hormone therapy did not provide a clinical benefit to postmenopausal patients with HR-positive, early-stage breast cancer, according to findings from the phase III TEAM IIB trial.
Neoadjuvant Abemaciclib Active in HR+/HER2- Breast Cancer
A neoadjuvant regimen combining the CDK4/6 inhibitor abemaciclib with anastrozole induced a response rate of 54.7% in patients with HR+/HER2-negative early-stage breast cancer, according to findings from the phase II neoMONARCH trial.
Hormonal Therapy Effectively Added to Dual HER2-Blockade in Phase II PERTAIN Study
The addition of an aromatase inhibitor (AI) to pertuzumab and trastuzumab improved progression-free survival by 3.09 months, when compared with trastuzumab plus an AI.
Buparlisib Combo Modestly Effective in Pretreated HR+ Breast Cancer
Median progression-free survival was improved by 2.1 months with the addition of the pan-PI3K inhibitor buparlisib to fulvestrant for women with HR-positive/HER2-negative advanced breast cancer who received a prior aromatase inhibitor and progressed on or after an mTOR inhibitor.
Six Years of Anastrozole After Adjuvant Tamoxifen Not Better Than 3 Years
First results from the phase III DATA study show no advantage to extending anastrozole therapy from 3 years to 6 for the primary endpoint of 5-year adapted disease-free survival.
Mixed Results on Benefit of Extending Letrozole Beyond 5 Years of Prior Endocrine Therapy
Extending letrozole therapy in women with early-stage, HR-positive breast cancer who completed 5 years of prior hormone therapy did not yield a statistically significant improvement in either disease-free or overall survival, but prolonged use of the aromatase inhibitor may be beneficial in some subgroups of women with a higher risk of recurrence.
Genomic Study Uncovers Resistance Mutations in ER+ Breast Cancer
The genomic landscape of recurrent metastatic estrogen receptor–positive breast cancer differed significantly from the mutational profile of primary disease in a study that sheds light on acquired resistance mechanisms to anticancer therapies.
TILs Associated With Survival for Advanced HER2+ Breast Cancer
Higher levels of tumor-infiltrating lymphocytes were associated with improvements in overall survival for patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab in the phase III CLEOPATRA trial.
Veliparib Regimen Nears 80% Response Rate in BRCA+ Breast Cancer
Adding the PARP inhibitor veliparib to carboplatin/paclitaxel chemotherapy induced a response rate of 77.8% in patients with advanced BRCA-positive breast cancer.
Everolimus Added to Fulvestrant Doubles PFS in HR+ Breast Cancer
The addition of everolimus (Afinitor) to fulvestrant (Faslodex) significantly improved progression-free survival rates in postmenopausal patients with metastatic hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.
FDA Approval of a Biosimilar, Promising Data in Myeloma and GBM, and More
NGS Testing Is Essential Before Induction in NSCLC
Outlook in Treating Patients With Ovarian Cancer
IMpower-150: EGFR-Mutated Subset Analysis
Dr. Rajdev on the Difference Between Cancers and Carcinomas in NETs
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.